Efentakis, P.; Andreadou, I.; Iliodromitis, K.E.; Triposkiadis, F.; Ferdinandy, P.; Schulz, R.; Iliodromitis, E.K.
Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost. Int. J. Mol. Sci. 2022, 23, 14121.
https://doi.org/10.3390/ijms232214121
AMA Style
Efentakis P, Andreadou I, Iliodromitis KE, Triposkiadis F, Ferdinandy P, Schulz R, Iliodromitis EK.
Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost. International Journal of Molecular Sciences. 2022; 23(22):14121.
https://doi.org/10.3390/ijms232214121
Chicago/Turabian Style
Efentakis, Panagiotis, Ioanna Andreadou, Konstantinos E. Iliodromitis, Filippos Triposkiadis, Péter Ferdinandy, Rainer Schulz, and Efstathios K. Iliodromitis.
2022. "Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost" International Journal of Molecular Sciences 23, no. 22: 14121.
https://doi.org/10.3390/ijms232214121
APA Style
Efentakis, P., Andreadou, I., Iliodromitis, K. E., Triposkiadis, F., Ferdinandy, P., Schulz, R., & Iliodromitis, E. K.
(2022). Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost. International Journal of Molecular Sciences, 23(22), 14121.
https://doi.org/10.3390/ijms232214121